|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.05 BRL | +1.62% |
|
+1.03% | -23.78% |
| 06-29 | Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program | MT |
| 06-29 | Lilly, Regeneron selected for US program to review new manufacturing plants faster | RE |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 63,455 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | -19.87% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 55,541 | 52,770 | 49,445 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | -24.22% | -4.99% | -6.3% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 16.1x | 13x | 11.2x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 1.88x | 1.64x | 1.45x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | -2.34x | 0.5x | 0.7x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 4x | 3.62x | 3.35x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 3.5x | 3.01x | 2.61x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 9.44x | 8.41x | 6.86x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 10.3x | 8.22x | 6.74x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 10.7x | 8.32x | 7.09x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 9.39% | 12% | 14.1% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.932 | 4.42 | 4.955 |
| Rate of return | - | - | - | - | 0.46% | 0.63% | 0.71% | 0.79% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 38.63 | 48.1 | 55.44 |
| Distribution rate | - | - | - | - | 8.49% | 10.2% | 9.19% | 8.94% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 15,880 | 17,553 | 18,940 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 5,886 | 6,278 | 7,211 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 5,369 | 6,421 | 7,341 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 4,088 | 5,133 | 5,788 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -7,913 | -10,685 | -14,010 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 623.54 | 623.54 | 623.54 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 101,739 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/2/24 | 2/4/25 | 1/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 28.32x | 5.77x | 16.88x | 0.56% | 57.29B | |
| 35.89x | 12.16x | 23.03x | -.--% | 43.45B | |
| -56.58x | 3.05x | 9x | 3.59% | 38.02B | |
| 34.98x | 3.72x | 11.41x | -.--% | 31.98B | |
| -8.06x | 11.55x | -7.04x | -.--% | 27.66B | |
| 16.64x | 3.17x | 9.59x | -.--% | 22.91B | |
| 50.41x | 5.55x | 38.45x | -.--% | 17.74B | |
| 25.58x | 5.32x | 14.26x | -.--% | 16.45B | |
| -33.1x | 15.4x | -46.83x | -.--% | 14.1B | |
| Average | 10.45x | 7.30x | 7.64x | 0.46% | 29.96B | |
| Weighted average by Cap. | 11.70x | 7.00x | 10.97x | 0.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
